Total of $14 million (1.87 billion JPY) was raised in the Series C round, and cumulative $35 million (4.6 billion JPY, including grants) has been raised to date. Metcela is aiming to create new therapeutic options for heart failure by establishing an ecosystem for autologous cell therapy.
Through this acquisition, Metcela will add an autologous cell product for pediatric congenital heart disease to its pipeline and significantly strengthen its clinical development infrastructure for regenerative medicine products.
Metcela intends to significantly strengthen its collaboration with Osaka University and Tohoku University in its future development activities through this financing.